Suchergebnisse - "Best, Jennie H"

PubPharm (33)

11

Comparative Cost per Response for 4 Clinical Endpoints with Tocilizumab Monotherapy vs Adalimumab Monotherapy in a Head-to-Head Randomized Double-Blind Superiority Trial (ADACTA) in Patients with Rheumatoid Arthritis

enthalten in: Rheumatology and therapy | 2020

von Best, J. | Vlad, S. | Pei, J.

12

Risk of Potential Glucocorticoid-Related Adverse Events in Patients with Giant Cell Arteritis : Results from a USA-Based Electronic Health Records Database

enthalten in: Rheumatology and therapy | 2019

von Best, J. | Kong, A. | Unizony, S. | +2

13

Healthcare Costs of Potential Glucocorticoid-Associated Adverse Events in Patients with Giant Cell Arteritis

enthalten in: ClinicoEconomics and outcomes research : CEOR | 2019

von Best, J. | Kong, A. | Smith, D. | +2

14

Costs of Disease Relapses Among Individuals with Granulomatosis, with Polyangiitis, or Microscopic Polyangiitis in the United States

enthalten in: Rheumatology and therapy | 2018

von Kong, A. | Kim, G. | Michalska, M. | +1

15

Association Between Glucocorticoid Exposure and Healthcare Expenditures for Potential Glucocorticoid-related Adverse Events in Patients with Rheumatoid Arthritis

enthalten in: The Journal of rheumatology | 2018

von Best, J. | Kong, A. | Lenhart, G. | +3

CommentIn: J Rheumatol. 2018 Mar;45(3):293-296. - PMID 29496913

16

Effectiveness of biologic and non-biologic antirheumatic drugs on anaemia markers in 153,788 patients with rheumatoid arthritis : New evidence from real-world data

enthalten in: Seminars in arthritis and rheumatism | 2018

von Paul, S. | Montvida, O. | Best, J. | +3

17

Estimating the Cost of Illness of Giant Cell Arteritis in the United States

enthalten in: Rheumatology and therapy | 2017

von Babigumira, J. | Li, M. | Boudreau, D. | +2

18

Comparison of trajectories of self-monitored glucose levels by hypoglycemia status over 52 weeks of treatment with insulin glargine or exenatide once weekly

enthalten in: Journal of diabetes | 2016

von Paul, S. | Agbeve, J. | Maggs, D. | +1

19

Dynamic risk factors associated with non-severe hypoglycemia in patients treated with insulin glargine or exenatide once weekly

enthalten in: Journal of diabetes | 2015

von Paul, S. | Maggs, D. | Klein, K. | +1

20

The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes : a retrospective observational study

enthalten in: Cardiovascular diabetology | 2015

von Paul, S. | Klein, K. | Maggs, D. | +1